节点文献

扩张型心肌病发病机理及治疗进展

Progress of pathogenesis and treatment in dilated cardiomyopathy

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 王玉亭王庭槐

【Author】 WANG Yu-ting, WANG Ting-huai. Department of Internal Medician. Beichen Hospital, Tianjin 300400, China

【机构】 天津市北辰医院内科天津市北辰医院内科 天津300400天津300400教授博士生导师

【摘要】 扩张型心肌病(DCM)以左心室或双心室扩张及收缩功能受损为特征,其发病机理主要与病毒感染后的自身免疫反应有关。80年代以后,遗传因素与DCM的关系逐渐受到重视。DCM的基本治疗是纠正心力衰竭,心律失常及预防血栓栓塞等并发症。针对免疫介导的心肌损伤的早期干预已成为DCM的主要治疗方法。在DCM早期应用地尔硫ö和β-受体阻滞剂治疗,可以阻止免疫介导的心肌损害,改善患者预后。

【Abstract】 Dilated cardiomyopathy (DCM) is characterized by the dilatation of left ventricle or biventrical accompanied by the impairment of the contractile force. The pathogenesis is concerned to have some connection with autoimmunity after infection for virus. Later of 1980’s, it is more and more taken seriously that the relationship between genecics and DCM. The primary therapy for DCM is to cure complications including congestive heart failure, arrhythmia and thromboembolism. Intervention in early stage to aim directly at the myocardium impairment mediated by immunity is the main therapy for DCM. If treated with diltiazem and beta-adrenergic blocage in early stage of DCM, cardiac injury would be prevented and the prognosis improved.

【关键词】 扩张型心肌病发病机理治疗
【Key words】 Dilated cardiomyopathyPathogenesisTherapy
  • 【文献出处】 中国心血管杂志 ,Chinese Journal of Cardiovascular Medicine , 编辑部邮箱 ,2005年03期
  • 【分类号】R542.2
  • 【被引频次】54
  • 【下载频次】835
节点文献中: 

本文链接的文献网络图示:

本文的引文网络